Selected Publications
Ahmed SR, Bellamkonda S, Zilbermint M, et alEffects of the low carbohydrate, high fat diet on glycemic control and body weight in patients with type 2 diabetes: experience from a community-based cohort BMJ Open Diabetes Research and Care 2020;8:e000980. doi: 10.1136/bmjdrc-2019-00098
Haque W , Ahmed SR, Zilbermint M Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrinetumor, Journal of Community Hospital Internal Medicine Perspectives 2020; 10(4): 338-339, DOI:10.1080/20009666.2020.1771126T
Ahmed SR, Azad NS, Ball DW, Rudek MA, Nelkin B, Cosgrove D, Gong J, Finkelstein F, Zahurak M, Janku F, Downs M, O'Connor A, Markus S, Carducci MA, Sherman SI, Kurzrock R. A Phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/Raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. J Clin Oncol. 2012:30 (suppl;abstr TPS3117) Presented at the American Society of Clinical Oncology Meeting, Chicago, 2012
Ahmed SR, Ball DW. Incidentally-discovered Medullary Thyroid Cancer: Diagnostic strategies and treatment. J Clin Endocrinol and Metab 2011: 96 (5):1237-1245
Ahmed SR, Cosgrove D, Ball D, Donehower R, Nelkin B, Petito E, Downs M, Scardina A, Carducci M, Azad N. A Phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. J Clin Oncol. 2011(suppl; abstr TPS156) Presented at the American Society of Clinical Oncology Meeting, Chicago, 2011, 2012